It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Type I interferon (IFN) signalling is tightly controlled. Upon recognition of DNA by cyclic GMP-AMP synthase (cGAS), stimulator of interferon genes (STING) translocates along the endoplasmic reticulum (ER)-Golgi axis to induce IFN signalling. Termination is achieved through autophagic degradation or recycling of STING by retrograde Golgi-to-ER transport. Here, we identify the GTPase ADP-ribosylation factor 1 (ARF1) as a crucial negative regulator of cGAS-STING signalling. Heterozygous ARF1 missense mutations cause a previously unrecognized type I interferonopathy associated with enhanced IFN-stimulated gene expression. Disease-associated, GTPase-defective ARF1 increases cGAS-STING dependent type I IFN signalling in cell lines and primary patient cells. Mechanistically, mutated ARF1 perturbs mitochondrial morphology, causing cGAS activation by aberrant mitochondrial DNA release, and leads to accumulation of active STING at the Golgi/ERGIC due to defective retrograde transport. Our data show an unexpected dual role of ARF1 in maintaining cGAS-STING homeostasis, through promotion of mitochondrial integrity and STING recycling.
Self-derived DNA may trigger interferon-driven autoinflammation mediated by the cGAS-STING axis. Here, the authors find that mutations in the GTPase ARF1 cause an interferonopathy by promoting aberrant mitochondrial DNA release and impairing STING recycling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Ulm University Medical Center, Institute of Molecular Virology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
2 Université Paris Cité, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR1163, Paris, France (GRID:grid.462336.6)
3 Ulm University, Central Facility for Electron Microscopy, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
4 Technical University of Munich, Institute of Virology, Munich, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966)
5 Ulm University, Institute of Biophysics, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
6 Ulm University, Core Unit Mass Spectrometry and Proteomics, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
7 IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109); Università degli Studi di Genova, Genoa, Italy (GRID:grid.5606.5) (ISNI:0000 0001 2151 3065)
8 IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy (GRID:grid.419504.d) (ISNI:0000 0004 1760 0109)
9 Children’s Health Ireland, Crumlin, Dublin, Eire (GRID:grid.417322.1) (ISNI:0000 0004 0516 3853); University College Dublin, Dublin, Eire (GRID:grid.7886.1) (ISNI:0000 0001 0768 2743)
10 St. Olav’s Hospital, Department of Medical Genetics, Trondheim, Norway (GRID:grid.52522.32) (ISNI:0000 0004 0627 3560)
11 Haukeland University Hospital, Department of Medical Genetics, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393)
12 University of California, Division of Genomic Medicine, Department of Pediatrics, Davis in Sacramento, USA (GRID:grid.27860.3b) (ISNI:0000 0004 1936 9684); Rady Children’s Institute for Genomic Medicine, San Diego, USA (GRID:grid.286440.c) (ISNI:0000 0004 0383 2910)
13 Rady Children’s Hospital San Diego, Division of Pediatric and Adolescent Dermatology, San Diego, USA (GRID:grid.286440.c) (ISNI:0000 0004 0383 2910); University of California San Diego School of Medicine, Department of Dermatology, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
14 Rady Children’s Institute for Genomic Medicine, San Diego, USA (GRID:grid.286440.c) (ISNI:0000 0004 0383 2910)
15 Université Paris Cité, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR1163, Paris, France (GRID:grid.462336.6); University of Edinburgh, MRC Human Genetics Unit, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)